These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24516212)

  • 21. Partnering for therapeutics discovery.
    Colvis CM; Devaney S; Brady LS; Hudson KL
    Clin Pharmacol Ther; 2013 Jan; 93(1):24-5. PubMed ID: 23187876
    [No Abstract]   [Full Text] [Related]  

  • 22. Cross-boundary cancer studies at the University of Tokyo: Measures to control cancer in Japan.
    Kakizoe T
    Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i38-42. PubMed ID: 24516211
    [No Abstract]   [Full Text] [Related]  

  • 23. Project data sphere to make cancer clinical trial data publicly available.
    Hede K
    J Natl Cancer Inst; 2013 Aug; 105(16):1159-60. PubMed ID: 23904505
    [No Abstract]   [Full Text] [Related]  

  • 24. New paradigms for cancer drug discovery.
    Sager JA; Lengauer C
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S178-81. PubMed ID: 14508097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Companies waver in efforts to target transforming growth factor beta in cancer.
    Garber K
    J Natl Cancer Inst; 2009 Dec; 101(24):1664-7. PubMed ID: 19933941
    [No Abstract]   [Full Text] [Related]  

  • 26. Market watch: Therapeutic area 'heat map' for emerging markets.
    Gautam A; Li L; Srinivasan K
    Nat Rev Drug Discov; 2015 Aug; 14(8):518-9. PubMed ID: 26160486
    [No Abstract]   [Full Text] [Related]  

  • 27. Realigning interests.
    Nat Biotechnol; 2011 Mar; 29(3):171. PubMed ID: 21389989
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug development research: diabetes favored over cardiovascular disease?
    Suckling K
    Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
    [No Abstract]   [Full Text] [Related]  

  • 29. The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials.
    Tran DT; Akpinar I; Fedorak R; Jonsson E; Mackey J; Richer L; Jacobs P
    J Pharm Pharm Sci; 2017; 20(1):407-414. PubMed ID: 29197429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
    Rai AK; Reichman JH; Uhlir PF; Crossman C
    Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
    [No Abstract]   [Full Text] [Related]  

  • 31. Large drug firms narrow their therapeutic interests.
    Mullard A
    Lancet; 2014 May; 383(9932):1873. PubMed ID: 24892171
    [No Abstract]   [Full Text] [Related]  

  • 32. The RACE to accelerate drug development for children with cancer.
    Pearson ADJ; Karres D; Reaman G; DuBois SG; Knox L; Scobie N; Vassal G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):714-716. PubMed ID: 32822672
    [No Abstract]   [Full Text] [Related]  

  • 33. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
    Honig PK
    Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan.
    Boku N
    Jpn J Clin Oncol; 2010 Mar; 40(3):183-7. PubMed ID: 20047861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small study on industry trial sponsorship leads to big questions about quality and bias.
    Twombly R
    J Natl Cancer Inst; 2007 Jul; 99(13):988-90. PubMed ID: 17596566
    [No Abstract]   [Full Text] [Related]  

  • 36. Academia and industry: allocating credit for discovery and development of new therapies.
    Flier JS
    J Clin Invest; 2019 May; 129(6):2172-2174. PubMed ID: 31107243
    [No Abstract]   [Full Text] [Related]  

  • 37. Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.
    Adam M
    Stud Hist Philos Biol Biomed Sci; 2005 Sep; 36(3):513-37. PubMed ID: 16137601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond genomics.
    Dollery CT
    Clin Pharmacol Ther; 2007 Oct; 82(4):366-70. PubMed ID: 17851575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adventure! Comedy! Tragedy! Robots! How bioethicists learned to stop worrying and embrace their inner cyborgs.
    Elliott C
    J Bioeth Inq; 2005; 2(1):18-23. PubMed ID: 16025606
    [No Abstract]   [Full Text] [Related]  

  • 40. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.